COMP <GO>
TNGX vs MRK // FORWARD P/E MULTIPLE
Tango Therapeutics Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: TNGX 3
— MRK 11
▲ FORWARD P/E MULTIPLE LEADER: MRK
LAST: $22.72 (+0.84%) • MKT CAP: $3.80B
forward-pe
28.0x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
forward-pe
18.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TNGX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TNGX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.90% | 20.70% | -49.60 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.68% | 3.42% | -7.10 | MRK | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.10% | -88.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 48.30% | 1.30% | +47.00 | TNGX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.19 | +20.81 | TNGX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.60% | -0.10 | TNGX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.7 | 56.9 | -10.17 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 0.92 | -0.05 | MRK | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 28.0x | 18.4x | +9.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.80B | $361.02B | -$357.22B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TNGX REV | MRK REV | TNGX GROSS % | MRK GROSS % | TNGX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $62.4M | $65.01B | 44.0% | 74.8% | -$139.9M | $12.36B |
| FY 2024 | $42.1M | $64.17B | 44.0% | 76.3% | -$132.3M | $18.10B |
| FY 2023 | $36.5M | $60.12B | 44.0% | 44.0% | -$119.6M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TNGX // BETA 0.87
MRK // BETA 0.92